| Randall Feuer, MD | |
|
21301 Kuykendahl Rd, Spring, TX 77379 | |
| (346) 336-6904 | |
| (346) 336-6910 |
| Full Name | Randall Feuer |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 21301 Kuykendahl Rd, Spring, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043291362 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | G2132 (Texas) | Primary |
| Entity Name | Randall Feuer Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295350031 PECOS PAC ID: 8022431527 Enrollment ID: O20200630002591 |
News Archive
Hospitals that use a simple strategy of enhancing communication with family members of patients dying in the intensive care unit can greatly reduce post-traumatic stress disorder, anxiety and depression after their loved one dies, according to a study to be presented at the American Thoracic Society International Conference in San Francisco.
Cannabis use appears to be associated with an earlier onset of psychotic illness, according to a meta-analysis of previously published studies posted online today that will appear in the June print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Hospira, Inc., a global specialty pharmaceutical and medication delivery company, today announced the successful completion of the tender offer by Discus Acquisition Corporation, a wholly owned Hospira subsidiary, to purchase all outstanding shares of the common stock of Javelin Pharmaceuticals, Inc..
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
An exhibition entitled "The Birth of Immunology" during the 2nd European Congress of Immunology from13th to 16th September 2009 at the main foyer of the ICC in Berlin will offer insights into the fast-paced history of immunology. Immunology has promoted medical progress since the end of the 19th century like almost no other discipline.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Randall Feuer, MD 21301 Kuykendahl Rd, Spring, TX 77379 Ph: (346) 336-6904 | Randall Feuer, MD 21301 Kuykendahl Rd, Spring, TX 77379 Ph: (346) 336-6904 |
News Archive
Hospitals that use a simple strategy of enhancing communication with family members of patients dying in the intensive care unit can greatly reduce post-traumatic stress disorder, anxiety and depression after their loved one dies, according to a study to be presented at the American Thoracic Society International Conference in San Francisco.
Cannabis use appears to be associated with an earlier onset of psychotic illness, according to a meta-analysis of previously published studies posted online today that will appear in the June print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Hospira, Inc., a global specialty pharmaceutical and medication delivery company, today announced the successful completion of the tender offer by Discus Acquisition Corporation, a wholly owned Hospira subsidiary, to purchase all outstanding shares of the common stock of Javelin Pharmaceuticals, Inc..
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
An exhibition entitled "The Birth of Immunology" during the 2nd European Congress of Immunology from13th to 16th September 2009 at the main foyer of the ICC in Berlin will offer insights into the fast-paced history of immunology. Immunology has promoted medical progress since the end of the 19th century like almost no other discipline.
› Verified 1 days ago
Dr. William Min-choy Chen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8411 Louetta Rd, Spring, TX 77379 Phone: 281-893-5870 Fax: 281-893-5895 | |
Mohammad Nameer Sidiquee, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7105 Fm 2920 Rd, Spring, TX 77379 Phone: 281-737-0902 | |
Dr. Andrew Spafford, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6401 Cypresswood Dr, Suite 180, Spring, TX 77379 Phone: 281-866-7080 Fax: 281-866-7151 | |
Huong T Le, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2306 Rayford Rd, Spring, TX 77386 Phone: 281-453-7777 | |
Marissa Pangan, FNP-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3466 Discovery Creek Blvd, Spring, TX 77386 Phone: 281-440-5300 | |
Mrs. Sushma V Gorrela, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6225 Fm 2920 Rd, Suite 100, Spring, TX 77379 Phone: 281-257-5977 Fax: 281-257-5966 |